ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $4.58M rose 36.6% year over year, ahead of the +24.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at +26.7% a year.
Context
- Cost of revenue amounted to 38.6% of revenue in FY2025, down 0.5 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +36.6% holds above the trailing-twelve-month pace of +24.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 14.28M USD
- Year-over-year change
- +16.4%
- 4-year CAGR
- +28.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.28M | +16.4% |
| FY2024 | 2024-12-31 | 12.27M | +18.6% |
| FY2023 | 2023-12-31 | 10.34M | +47.3% |
| FY2022 | 2022-12-31 | 7.02M | +35.6% |
| FY2021 | 2021-12-31 | 5.18M | — |
Cost of Revenue vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.0% is the highest of 9, against a peer median of +2.1%.
- Cost of revenue amounts to 38.2% of revenue for CLPT, versus a peer median of 49.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$682.57M CAD | +0.2% | +6.3% | 72.8% | |
| LTM Apr 2026 | $569.8M USD | +3.9% | -1.3% | 66.4% | |
| LTM Mar 2026 | $368.3M USD | +18.2% | +6.7% | 51.4% | |
| LTM Mar 2026 | $255.74M USD | -3.2% | +29.9% | 31.0% | |
| LTM Mar 2026 | $98.61M USD | +11.1% | +15.4% | 48.3% | |
| LTM Mar 2026 | $44.6M USD | -34.2% | -11.1% | 51.7% | |
| LTM Mar 2026 | $44.46M USD | -11.9% | +20.6% | 19.1% | |
| LTM Mar 2026 | $42.1M USD | +14.9% | +37.7% | 20.4% | |
| LTM Mar 2026 | $15.51M USD | +24.0% | +26.7% | 38.2% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding CLPT) | — | +2.1% | +11.1% | 49.9% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.